SCHEMBL7824907

SCHEMBL7824907

O=C(O)c1ccccc1C(=O)n1ccnc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 1/20 0.48
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
CYP19A1 P11511 1/20 0.42
TBXAS1 P24557 2/20 0.41
CYP24A1 Q07973 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
APEX1 P27695 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
AKR1C3 P42330 1/20 0.40
DHODH Q02127 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30366356 0.93 FAAH (0.44) ALDH1A1FAAHMGLLCYP19A1TBXAS1
SCHEMBL31664989 0.81 ALDH1A1 (0.50) ALDH1A1ALOX15FAAHMGLLTDP1
SCHEMBL395689 0.81 MAPT (0.44) FAAHMGLLCYP19A1TBXAS1CYP24A1
SCHEMBL10506862 0.81 KMT2A (0.48) ALDH1A1CYP19A1POLBKDM4E
SCHEMBL16486800 0.81 TBXAS1 (0.42) ALDH1A1ALOX15FAAHMGLLCYP19A1
SCHEMBL15763697 0.81 ELANE (0.55) ALDH1A1L3MBTL1
SCHEMBL1424751 0.80 CYP19A1 (0.47) FAAHMGLLCYP19A1TBXAS1CYP24A1
SCHEMBL20572807 0.80 MAPT (0.43) FAAHMGLLCYP19A1TBXAS1CYP24A1
SCHEMBL10118094 0.79 ALDH1A1 (0.54) ALDH1A1TBXAS1POLBL3MBTL1KDM4E
SCHEMBL11277690 0.77 ALDH1A1 (0.61) ALDH1A1ALOX15NAPRTTDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091996-A1 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND UNIV KING FAISAL (SA) 2025-03-20 US claimed
US-12172966-B1 2-(1H-imidazole-1-carbonyl)benzoic acid as an anticancer compound King Faisal University (SA) 2024-12-24 US claimed
US-20250091996-A1 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND UNIV KING FAISAL (SA) 2025-03-20 US disclosed
US-20250091996-A1 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND UNIV KING FAISAL (SA) 2025-03-20 US disclosed
US-20250091996-A1 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND UNIV KING FAISAL (SA) 2025-03-20 US disclosed
US-12172966-B1 2-(1H-imidazole-1-carbonyl)benzoic acid as an anticancer compound King Faisal University (SA) 2024-12-24 US disclosed
US-12172966-B1 2-(1H-imidazole-1-carbonyl)benzoic acid as an anticancer compound King Faisal University (SA) 2024-12-24 US disclosed
US-12172966-B1 2-(1H-imidazole-1-carbonyl)benzoic acid as an anticancer compound King Faisal University (SA) 2024-12-24 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172966-B1 2-(1H-imidazole-1-carbonyl)benzoic acid as an anticancer compound BAK1, BET1, NFKBIA ALDH1A1 288/4885ALOX15 3082/4885FAAH 3774/4885
US-20250091996-A1 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND BAK1, BET1, NFKBIA ALDH1A1 288/4885ALOX15 3082/4885FAAH 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.